MedTrace Logo

Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

NCT01424436 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2017-06-14

No results posted yet for this study

Summary

Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment

Conditions

Interventions

BIOLOGICAL

GSK933776

1mg/kg dose group

BIOLOGICAL

GSK933776

3mg/kg dose group

BIOLOGICAL

GSK933776

6mg/kg dose group

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-19
Primary Completion
2011-12-08
Completion
2011-12-08

Countries

  • Germany
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01424436 on ClinicalTrials.gov